Table 3.
Results of subgroup analyses for pNFH.
| Variables | P for Q-test | I2 statistics | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Case-control studies | 0.041 | 60 | 0.83 (0.79–0.87) | 0.85 (0.76–0.90) | 5.4 (3.3–8.7) | 0.20 (0.15–0.26) | 28 (14–55) | 0.89 (0.86–0.91) |
| Cutoff <1000 pg/mL | 0.032 | 64 | 0.83 (0.79–0.87) | 0.84 (0.75–0.90) | 5.3 (3.3–8.7) | 0.20 (0.15–0.26) | 27 (14–53) | 0.88 (0.85–0.91) |
| ELISA method | 0.091 | 41 | 0.85 (0.81–0.89) | 0.84 (0.76–0.90) | 5.5 (3.4–8.7) | 0.17 (0.13–0.24) | 32 (16–65) | 0.91 (0.88–0.93) |
| ALS only | 0.112 | 33 | 0.85 (0.78–0.90) | 0.86 (0.78–0.91) | 6.1 (3.7–9.8) | 0.18 (0.12–0.26) | 34 (16–73) | 0.92 (0.89–0.94) |
| R-El Escorial only | 0.08 | 45 | 0.82 (0.79–0.86) | 0.82 (0.74–0.89) | 4.6 (4.0–7.0) | 0.21 (0.17–0.26) | 22 (13–36) | 0.85 (0.82–0.88) |
| Europe and America | 0.04 | 60 | 0.83 (0.78–0.88) | 0.86 (0.77–0.92) | 6.0 (3.5–10.2) | 0.19 (0.14–0.26) | 31 (15–66) | 0.90 (0.87–0.92) |
| NC only | 0.465 | 0 | 0.86 (0.78–0.91) | 0.81 (0.73–0.87) | 4.5 (3.0–6.7) | 0.18 (0.11–0.29) | 25 (10–62) | 0.90 (0.87–0.92) |
ALS, amyotrophic lateral sclerosis; AUC, area under curve; DOR, diagnostic odd ratio; NC, neurological control; NLR, negative likelihood ratio; PLR, positive likelihood ratio; pNFH, phosphorylated neurofilament heavy chain, R-El Escorial, revised El Escorial.